Fas-associated death domain-containing protein (FADD), a classical apoptotic signaling adaptor, participates in different nonapoptotic processes regulated by its phosphorylation. However, the influence of FADD on metabolism, especially glucose homeostasis, has not been evaluated to date. Here, using both two-dimensional electrophoresis and liquid chromatography linked to tandem mass spectrometry (LC/MS/MS), we found that glycogen synthesis, glycolysis, and gluconeogenesis were dysregulated because of FADD phosphorylation, both in MEFs and liver tissue of the mice bearing phosphorylation-mimicking mutation form of FADD (FADD-D). Further physiological studies showed that FADD-D mice exhibited lower blood glucose, enhanced glucose tolerance, and increased liver glycogen content without alterations in insulin sensitivity. Moreover, investigations on the molecular mechanisms revealed that, under basal conditions, FADD-D mice had elevated phosphorylation of Akt with alterations in its downstream signaling, leading to increased glycogen synthesis and decreased gluconeogenesis. Thus, we uncover a novel role of FADD in the regulation of glucose homeostasis by proteomic discovery and physiological validation. 

Molecular & Cellular Proteomics 12: 10.1074/mcp.M113.029306, 2689-2700, 2013.
balance of the storage of glucose as glycogen, the use of glucose through glycolysis, and the production of glucose via glycogenolysis and gluconegenesis in liver (20). Glycogen synthesis and breakdown (glycogenolysis) are predominantly controlled by the coordination of two enzymes, glycogen synthase (GS) and glycogen phosphorylase (GP) (21). Glycolysis, initiated by the enzyme glucokinase (Gck), converts glucose into pyruvate and further produces a final production of ethanol or lactate by a serial of reactions (22). Gluconegenesis is the opposite metabolic pathway of glycolysis, generating glucose from noncarbohydrate carbon substrates such as pyruvate, lactate, and so on (22, 23). Glucose-6-phosphatase (G6pc) and phosphoenolpyruvate carboxykinase (Pepck) are two rate-limiting enzymes for gluconegenesis (20, 24). In addition, glucose metabolism is under the control of several hormones, such as insulin and glucagon (25). Insulin plays an important role in glucose homeostasis by activating protein kinase B/Akt, the key node in insulin signaling (26, 27). The activated Akt can phosphorylate and inactivate glycogen synthase kinase (GSK) 3β, a key negative regulator in glycogen synthesis (28, 29). Meanwhile, Akt phosphorylates the forkhead transcription factor (Foxo1), promoting nuclear to cytoplasmic translocation of Foxo1 and suppressing Foxo1-dependent transcription, such as G6pc and Pepck (30, 31).

At present, proteomics coupled with bioinformatics analysis is increasingly used in biological research to fully understand the potential targets and signaling pathway networks (32). The proteomic platform provides a powerful tool for us to perform high-throughput studies allowing the detection of modulated proteins, which are regulated under abnormal conditions, and attempts to identify candidate pathways regulated by specific genes (33–35). In particular, the shotgun approach based on one-dimensional (1D) PAGE with liquid chromatography chip and Q-TOF MS/MS (HPLC-Chip/Q-TOF) allows the qualitative and quantitative analysis of a large number of proteins in complex samples, avoiding time-consuming two-dimensional electrophoresis (2-DE) and isotopic labeling (36). In this study, we first applied two-dimensional electrophoresis (2-DE)-proteomics approach to compare the different expression patterns of wild-type (WT) and FADD-D mouse embryonic fibroblasts (MEFs). Then, we further investigated WT and FADD-D livers by a label-free 1D-LC-MS/MS analysis using nanoLC coupled to a q-TOF mass spectrometer (HPLC-Chip/Q-TOF). Based on the information inherent in chromatographic data, MS spectra, and MS/MS-based peptide assignments, label-free quantitative strategies are attractive alternatives for quantitative LC/MS/MS-based proteomics because of their simplicity, affordability, and flexibility. Although suppressive ionization may affect the quantification, previous studies have demonstrated that spectral counting (peptide count), spectral ion intensity, or peak area of peptide ions correlates well with protein abundance in complex samples (37–39). Here, protein samples from two genotype livers were trypsinized before LC-MS analysis. Samples were analyzed in triplicates using 6550 nano HPLC-Chip/q-TOF mass spectrometer. The data were analyzed and semiquantified using Spectrum Mill bioinformatics tool. In total hundreds of proteins were found to be dysregulated because of FADD phosphorylation in both MEFs and livers. Using MetaCore™ pathway analysis tools, we identified a number of differentially expressed proteins involved in glycogen metabolism, glycolysis, and gluconegenesis, suggesting a novel role for FADD in glucose homeostasis. Therefore, we performed further physiological examinations on FADD-D mice to address this issue. Our data showed that FADD-D mice were hypoglycemic and had increased glucose tolerance. The hepatic glycogen accumulation in FADD-D mice was also enhanced. In addition, the phosphorylation form of Akt, a key regulator in glucose homeostasis (27, 40), was elevated in liver tissue of FADD-D mice. Collectively, these data suggest that FADD phosphorylation might have an impact on glucose homeostasis, revealing a novel function of FADD, which has not been evaluated to date.

**EXPERIMENTAL PROCEDURES**

**Stable Cell Line Construction and Cell Culture—WT MEFs and FADD-D MEFs were all cultured in DMEM (HyClone, Logan, UT) containing 10% FBS (HyClone) with 50 U/ml penicillin/streptomycin. FADD mutant cell line FADD-D was constructed based on FADD−/− MEFs; the construction and validation of the cell lines were performed in Dr. Astar Winoto’s Laboratory (UC Berkeley). Briefly, FADD-D mutant cDNAs were generated using PCR, as previously described (8), subcloned into the retroviral vector MSCV-Zeoicin and transfected into Bosc packing cells. Supernatant was used to infect FADD knock-out MEFs. Infected MEFs were selected with Zeocin for 1 month. The expression levels of FADD and FADD-D were examined using immunoblotting assay and were similar across different MEFs.**

**Two-dimensional Gel Electrophoresis and Matrix-assisted Laser Desorption Ionization-time-of-flight (MALDI-TOF) MS—MEFs (1 × 10^6) were all harvested when they reached 90% confluence, rinsed three times with ice-cold PBS and pelleted at 2000 g for 5 min. Then, the pellets were lysed in a cell lysis solution containing 7 M urea, 2 M thiourea, 40 mM dithiothreitol, and 2% IPG buffer (pH 3–10 L, GE Healthcare) at a volume ratio of 1:10. After cyclic liquid nitrogen freezing-thawing treatment, the lysates were sonicated in short bursts to disrupt nucleic acids, and then were centrifuged at 40,000 × g for 4°C for 60 min. The protein concentration in the supernatant was determined by the Bradford method. All procedures were performed on ice. The supernatant containing 120 μg proteins was first isoelectrically focused on a gel strip with 3–10 linear pH gradient, and then resolved on an SDS-polyacrylamide gel as previously reported (41). The separated proteins were visualized by silver staining as described before (42). After destaining with double bound water, gels were scanned at 300 dpi resolution, and the images were processed using the Adobe Photoshop software (Adobe Systems) and analyzed using the Image Master Platinum™ software (GE Healthcare) according to the manufacturer’s procedures. Over a twofold change in protein concentration was considered to be significant (p < 0.01 by Mann-Whitney test). The differentially expressed proteins were cut and digested essentially as described by Yang et al. (43).**

MALDI samples were prepared according to a thin layer method described before (43, 44). Mass spectra were recorded on an Ultraflex II MALDI-TOF-TOF mass spectrometer (Bruker Daltonics GmbH, Bre...
men, Germany) under the control of FlexControl™ 3.0 software (Bruker Daltonik). MALDI-TOF spectra were recorded in the positive ion reflector mode in a mass range from 700–4000 Da, and the ion acceleration voltage was 25 kV. Acquired mass spectra were processed using the software FlexAnalysis™ 3.0 (Bruker Daltonics); Peak detection algorithm: SNAP (Sort, Neaten, Assign, and Place); signal-to-noise (S/N) threshold: 3; Quality Factor Threshold: 50. The trypsin auto-digestion ion picks (trypsin[108–115], MH+ 842.509, trypsin[58–77], MH+ 2211.104) were used as internal standards. Matrix and/or auto-proteolytic trypsin fragments or known contaminant ions (keratins) were excluded. The resulting peptide mass lists were used to search the IPI mouse database 3.29 (53981 sequences, 25507684 residues) with Mascot (v2.3.02) in automated mode. The following criteria were used for search parameters: significant protein MOWSE score at p < 0.05, minimum mass accuracy 120 ppm, trypsin as enzyme, 1 miss cleaved site allowed, alkylation of cysteine by carbamidomethylation as fixed modification and oxidation of methionine as variable modification. In addition, the Mascot Score and expectation of the first nonhomologous protein to the highest ranked hit were checked.

Animals—All studies involving mice with high standard animal welfare were approved by Nanjing University Animal Care and Use Committee. Animals were housed in a specific pathogen-free animal facility on a 12-h light-dark cycle at an ambient temperature of 21 °C. They were given free access to water and food. Experiments were conducted in accordance with the requirements of the animal care and use guidelines of the institutional animal care and use committee. Animals were maintained in a specific pathogen-free animal facility on a 12-h light-dark cycle at an ambient temperature of 21 °C. They were given free access to water and food. Experiments were performed on mice aged between 8–10 weeks. Details of generating FADD-D mice have been described previously (8).

Protein Extraction, Separation, and Digestion—Proteins were extracted from fresh livers as described previously with some modifications (45). Briefly, minced livers were homogenized with 5 volumes of ice-cold lysis solution using a loose fitting Dounce homogenizer. Minced livers were homogenized with 5 volumes of ice-cold lysis solution using a loose fitting Dounce homogenizer. After filtering through four layers of nylon gauze, the homogenate was centrifuged at 12,000 × g for 10 min, and then the supernatant was collected and the protein concentration was determined using the Bradford protein assay kit (Bio-Rad, Hercules, CA). After being separated by SDS-PAGE, the PAGE was stained with Coomassie brilliant blue G-250 and cut into slices. Before MS analysis, the gel was treated with 100 mM ammonium bicarbonate (ABC)/50% acetonitrile (ACN) (1:1, v/v), and ACN was added to dehydrate. Subsequently, trypsin (10 ng/trypsin[108–115], MH+ 842.509, trypsin[58–77], MH+ 2211.104) was used as internal standards. Matrix and/or auto-proteolytic trypsin fragments or known contaminant ions (keratins) were excluded. The resulting peptide mass lists were used to search the IPI mouse database 3.29 (53981 sequences, 25507684 residues) with Mascot (v2.3.02) in automated mode. The following criteria were used for search parameters: significant protein MOWSE score at p < 0.05, minimum mass accuracy 120 ppm, trypsin as enzyme, 1 miss cleaved site allowed, alkylation of cysteine by carbamidomethylation as fixed modification and oxidation of methionine as variable modification. In addition, the Mascot Score and expectation of the first nonhomologous protein to the highest ranked hit were checked.

Blood glucose levels were then measured at 0, 15, 30, 60, and 90 min after the injection. For intraperitoneal insulin tolerance test (IPITT), mice were fasted for 6 h, followed by intraperitoneal insulin injection (0.5 U/kg). Blood glucose levels were then measured at 0, 15, 30, 60, and 90 min after the injection.

Glycogen Content—The glycogen content was determined according to the method described previously (47). Briefly, mice were fasted overnight and sacrificed. Liver samples (30–90 mg) were weighted and digested in 300 μl of 30% (w/v) KOH at the boiling water bath for 30 min. After the solution cooled to room temperature, 100 μl of 1 M Na2SO4 and 800 μl ethanol were added and boiled for 5 min to precipitate glycogen. The samples were centrifuged for 5 min at 10,000 rpm and the pellets were washed with 95% ethanol and dried on air. Pellets were reconstituted in 200 μl 0.2 M Na-acetate buffer (pH 4.8) and hydrolyzed with 1.25 mg/ml amyloglucosidase (Sigma-Aldrich, St. Louis, MO) at 55 °C for 2 h. Glucose concentration was determined using Glucose (GO) Assay Kit (Sigma-Aldrich, St. Louis, MO).

Histology—Livers collected from euthanized animals were fixed in 10% phosphate-buffered formalin and embedded in paraffin, then, 5-μm-thick sections were stained with hematoxylin and eosin (H&E) for routine histology. Liver sections were fixed in Carnoy solution (60% ethanol, 30% chloroform, 10% glacial acetic acid) for glycogen detection and stained with Periodic Acid-Schiff (PAS) Kit (Sigma-Aldrich, St. Louis, MO). For immunohistochemical staining, liver sections were immunostained with anti-GS antibody (Cell Signaling Technology, Beverly,
MA) and visualized with DAB. The localization of Foxo1 in liver was detected by staining liver sections with anti-Foxo1 antibody (Cell Signaling Technology, Beverly, MA) and Alexa Fluor 488-conjugated anti-rabbit IgG antibody (Invitrogen, Carlsbad, CA) was used as the secondary antibody. Nuclei were stained with Hoechst. The staining was monitored with an Axioskop2 microscope (Zeiss, Jena, Germany).

For electron microscopic examination, livers were fixed with 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4). The tissues were postfixed in 2% osmium tetroxide solution and embedded in epoxy resin. Sections were examined with electron microscope (Zeiss, Jena, Germany).

**Western Blotting**—Mice fasted overnight were injected intraperitoneally with 1 U/kg insulin. After 15 min, mice were sacrificed and tissues were collected. Livers were homogenized in lysis buffer. After centrifugation at 12,000 rpm, the supernatant was collected, and protein concentration was quantified by Bradford assays.

**RNA Extraction and Quantitative Real-time PCR**—Total RNA was extracted from tissues using a TRizol reagent (Invitrogen, Carlsbad, CA) following the manufacturer’s instructions and was used to prepare cDNA by PrimeScript RT reagent kit (Takara, Otsu, Shiga, Japan). Quantitative real-time PCR (qRT-PCR) was performed on an ABI system (Applied Biosystems, Foster City, CA). The primers used in the qRT-PCR were listed in supplemental Table S1. All data were means of fold change of triplicate analyses and normalized with those of GAPDH.

**Statistical Analysis**—Data were presented as means ± S.E. The difference between the two genotype groups was analyzed by two-tailed Student’s t test using Prism software (GraphPad, San Diego, CA). Values were considered statistically significant at p < 0.05.

**RESULTS**

**2-DE-Based Proteomics Analysis**—Considering the significance of serine 191 phosphorylation at FADD C-terminal region, we sought to reveal the molecular pathways directly or indirectly controlled by this phosphorylation and underscore its critical roles in nonapoptotic processes by the high throughput proteomic approaches. The confirmation of FADD-D MEF cell line was validated by Western blotting as shown in supplemental Fig. S1A. Proteomic profiling of FADD-D and wild type (WT) control MEFs was performed in parallel by two-dimensional electrophoresis analysis. supplemental Fig. S2 showed the typical 2-D gel images of the two cell lines respectively. A total of 35 proteins with their identified specific MS/MS sequences were identified after in-gel digestion, MALDI-TOF/TOF analysis, and IPI mouse database search. To further interpret the likely roles of differentially expressed proteins induced by FADD phosphorylation, we used the MetaCore™ pathway mapping tool to analyze and build the biological networks related to these proteins. GeneGo Map Folder analysis was applied to show that energy metabolism and its regulation have the highest significance. Fig. 1 showed detailed GeneGo Maps in Fold “energy metabolism and its regulation” among which insulin regulation of glycogen metabolism, glycolysis and gluconeogenesis were the most significant pathways. Six of the changed proteins were involved in these pathways (Table I and supplemental Fig. S3). supplemental Fig. S4A–S4C further displayed the pathway maps associated with glycogen metabolism, glycolysis, and gluconeogenesis. These results indicated that glucose metabolism may be dysregulated because of FADD phosphorylation in MEFs.

**HPLC-Chip/Q-TOF Based Proteomics Analysis**—To test whether FADD phosphorylation has a critical role on glucose metabolism, we generated FADD-D mice, an animal model containing FADD phosphorylation-mimicking mutation of serine residue at 191 on the background of FADD−/− (8). The expression levels of FADD and its phosphorylation form in livers of FADD-D and its littermate control mice were confirmed by Western blotting as shown in supplemental Fig. S1B. HPLC-Chip/Q-TOF technology was applied to quantitatively determine differentially expressed proteins between control and FADD-D mice livers. A t test identified 122 differential proteins. MetaCore™ pathway mapping tool revealed that seven proteins among them were involved in glycogen metabolism, glycolysis, and gluconeogenesis processes (Fig. 2 and Table II), which was partially consistent with the above cellular proteomics results. These data suggest a crucial role of FADD in glucose metabolism.
Low Blood Glucose Level in FADD-D Mice—To clarify the specific role of FADD phosphorylation on glucose metabolism physiologically, we examined blood glucose level in FADD-D mice, and found that FADD-D mice displayed notably lower fed and fasting blood glucose levels (Fig. 3A). Because glucose homeostasis is mainly regulated by insulin and glucagon (26, 48), we also detected their concentrations in serum. Fasting insulin levels were higher in FADD-D mice (Fig. 3B). In addition, glucagon, the counter-regulatory hormone of insulin, was about three times the level of control mice in FADD-D mice (Fig. 3C).

Improved Glucose Tolerance in FADD-D Mice—To further explore the effects of FADD-D on glucose homeostasis in vivo, we performed an intraperitoneal glucose tolerance test (IPGTT). In an IPGTT assay, the glucose levels were significantly decreased in FADD-D mice (Fig. 3D) and the incremental area under the blood glucose curve of FADD-D mice was only about two-thirds of that in control mice (Fig. 3E), indicating an improved glucose clearance in FADD-D mice after a glucose challenge.

Table I: Deregulated proteins involved in glycolysis and gluconeogenesis in FADD-D cells compared to FADD cells. The identification information for each protein is documented in supplemental File S1.

| Spot No. | Ratio of FADD-D to FADD | Identified protein | Network objects | NCBI accession No. | Coverage matched peptides | MowseScore |
|----------|-------------------------|-------------------|-----------------|--------------------|--------------------------|------------|
| 1        | -2.45                   | Phosphoenolpyruvate carboxykinase, mitochondrial precursor | PPCKM | GI:52783203 | 31% | 125 |
| 2        | 3.13                    | Glucokinase       | HXK4 | GI:1708365 | 33% | 110 |
| 3        | -2.78                   | Glucose-6-phosphatase | G6PT | GI:341940721 | 41% | 148 |
| 4        | 3.79                    | Phosphoglycerate mutase 1 | PGAM1 | GI:20178035 | 67% | 154 |
| 5        | 2.88                    | L-lactate dehydrogenase A chain | LDHA | GI:126048 | 36% | 159 |
| 6        | 2.86                    | Serine/threonine protein phosphatase PP1-alpha catalytic subunit (PP1 cat alpha) | PP1-cat | GI:49065812 | 30% | 85 |

Fig. 2. GeneGO pathway showing changes in expression of liver proteins involved in glycolysis and gluconeogenesis (A), insulin regulation of glycogen metabolism (B) upon FADD phosphorylation. The various proteins on this map are represented by different symbols (representing the functional class of the protein). Thermometers with blue or red shading next to symbols depict proteins identified in the present study: blue color represents the proteins that were down-regulated in FADD-D mice liver relative to control group; red color represents the proteins that were up-regulated in FADD-D mice liver relative to control group.

Low Blood Glucose Level in FADD-D Mice—To clarify the specific role of FADD phosphorylation on glucose metabolism physiologically, we examined blood glucose level in FADD-D mice, and found that FADD-D mice displayed notably lower fed and fasting blood glucose levels (Fig. 3A). Because glucose homeostasis is mainly regulated by insulin and glucagon (26, 48), we also detected their concentrations in serum. Fasting insulin levels were higher in FADD-D mice (Fig. 3B). In addition, glucagon, the counter-regulatory hormone of insulin, was about three times the level of control mice in FADD-D mice (Fig. 3C).

Improved Glucose Tolerance in FADD-D Mice—To further explore the effects of FADD-D on glucose homeostasis in vivo, we performed an intraperitoneal glucose tolerance test (IPGTT). In an IPGTT assay, the glucose levels were significantly decreased in FADD-D mice (Fig. 3D) and the incremental area under the blood glucose curve of FADD-D mice was only about two-thirds of that in control mice (Fig. 3E), indicating an improved glucose clearance in FADD-D mice after a glucose challenge.

The Intraperitoneal insulin tolerance test (IPITT) was also conducted to evaluate whether insulin sensitivity was
changed in FADD-D mice. After insulin injection, the blood glucose of FADD-D mice decreased to the level dramatically lower than that observed in littermates (Fig. 3F). But there was no significant difference in the relative decreased glucose from basal levels between FADD-D and control mice (Fig. 3G), suggesting that insulin sensitivity in FADD-D was unaltered.

**Increased Glycogen Accumulation in Liver of FADD-D Mice**—Blood glucose homeostasis is maintained by a balance between glucose production, uptake, and storage, which mainly take place in liver (20). So, we next examined the liver of these mice. Liver weights of FADD-D mice were decreased compared with their littermate controls (Fig. 4A). But when normalized to the body weight, the relative liver weight was significantly higher in FADD-D mice (Fig. 4B).

Histology analysis of liver showed there was no notable difference between FADD-D and control mice on Hematoxylin and Eosin (H&E) stains. Periodic acid-Schiff (PAS) staining revealed a remarkable increased hepatic glycogen accumulation in FADD-D mice (Fig. 4C), which was further confirmed by electron microscopy (Fig. 4D). In addition, the biochemical assay demonstrated that there was an approximate sixfold increase in hepatic glycogen content in FADD-D mice compared with littermate controls (Fig. 4E).

**Enhanced Akt Phosphorylation in FADD-D Mice**—To investigate the molecular mechanisms underlying the hypoglycemia and hepatic glycogen accumulation in FADD-D mice, we studied the insulin signaling, which plays a critical role in glucose homeostasis (26, 27). Under resting conditions, there was a significant increase in the phosphorylation of Akt in FADD-D mice liver (Figs. 5A and 5B). After insulin stimulation, FADD-D and control mice both had increased Akt phosphorylation. But, consistent with the above IPITT results, the amplification of Akt phosphorylation after insulin stimulation showed no significant difference between FADD-D and control mice (Fig. 5D), indicating unaltered insulin sensitivity in FADD-D mice.

Similar alterations were observed in glycogen synthase kinase (GSK) 3β (Figs. 5A, 5C, and 5E), a key negative regulator in glycogen synthesis downstream of Akt (28, 29). Because of the increased GSK3β phosphorylation under basal conditions, the unphosphorylated GSK3β, which is the active form

---

**TABLE II**

Deregulated proteins involved in glycolysis and gluconeogenesis in FADD-D mice liver compared to control mice liver. The identification information for each protein is documented in supplemental File S2

| No. | Identified protein                     | Network objects | Swiss-Prot No. | Molecular weight | Ratio of FADD-D to control |
|-----|---------------------------------------|-----------------|----------------|------------------|--------------------------|
| 1   | Glucose-6-phosphatase, catalytic       | G6PT            | P35576         | 40,473           | -1.97                    |
| 2   | Glucokinase (hexokinase 4)            | HKK4            | P52792         | 52,089           | 4.65                     |
| 3   | Phosphoenolpyruvate carboxykinase 1, cytosolic | PPCKC         | Q9Z2V4         | 69,355           | -2.34                    |
| 4   | Triosephosphate isomerase 1           | TPI1            | P17751         | 32,192           | -1.76                    |
| 5   | Pyruvate kinase isozymes R/L          | KPYR            | P53657         | 62,309           | 3.42                     |
| 6   | Fructose-bisphosphate aldolase A      | ALDOA           | P05064         | 39,356           | -1.68                    |
| 7   | Glycogen synthase, liver              | GYS2            | Q8VCB3         | 80,871           | 8.56                     |
and can phosphorylate and inactivate GS, was decreased. As a result, the activate form of unphosphorylated glycogen synthase (GS) was highly expressed in FADD-D mice correspondingly, as detected by Western blot and immunohistochemistry analyses of liver sections (Figs. 5A and 5F), leading to enhanced hepatic glycogen synthesis. The increased GS expression in FADD-D liver also confirmed our proteomics data.

In addition, as another downstream target of Akt, forkhead transcription factor (Foxo1) was also phosphorylated and a significant nuclear exclusion of Foxo1 was observed in liver sections of FADD-D mice compared with their littermates (Fig. 5G).

Expression of Genes Involved in Glucose Metabolism in FADD-D Mice—We next preformed qRT-PCR to analyze the expression of genes involved in glucose metabolism. Consistent with changes in insulin signaling and the above proteomics results, the mRNA levels of the two rate-limiting enzymes involved in gluconeogenesis and glycogenolysis glucose-6-phosphatase (G6pc) and phosphoenolpyruvate carboxykinase (Pepck) controlled by Foxo1 (30, 31), were down-regulated in liver tissues from FADD-D mice (Fig. 6A). Furthermore, the decreased hepatic Foxo1 mRNA level in FADD-D mice (Fig. 6A), together with the loss of function of Foxo1 by phosphorylation, led to suppression of G6pc and Pepck expression. Proteomics data indicated that Glucokinase (Gck), which is critical in glycogen synthesis and glycolysis (49), was highly expressed in FADD-D mice liver. The qRT-PCR analysis further confirmed the enhanced expression of Gck (Fig. 6B), accounting for the increased hepatic glycogen and low blood glucose observed in FADD-D mice. We also detected the mRNA expression of other changed enzymes identified in our proteomics analyses (Figs. 6B and 6C). In addition, we performed Western blots to verify the protein expression of these enzymes, which was mostly consistent with our proteomics results (Fig. 6D). In general, immunoblotting, qRT-PCR and physiological analyses confirmed the quantitative results detected by comparative proteomics. Thus, these data demonstrate for the first time that phosphorylation of FADD is associated with glucose homeostasis in vivo.

DISCUSSION

FADD serves as a critical adaptor in death receptor mediated apoptotic signaling. Further studies have revealed a novel role of “proliferation-apoptosis coupler” of FADD, which is assumed regulated by its phosphorylation (8, 17). Intriguingly, in this study, we uncover an unexpected role of FADD in glucose homeostasis, which may also be regulated by its phosphorylation.

Cellular and mice liver comparative proteomics revealed a special role for FADD in glycolysis and gluconeogenesis. Conventional 2-DE, in combination with advanced mass spectrometric techniques, has facilitated the rapid characterization of thousands of proteins in a single polycrylamide gel. However, several limitations and problem issues have been recognized: (1) Although silver staining has high sensitivity, it is worth paying special attention that this method has a narrow linear dynamic range, making it less suitable for quantification; (2) Proteins displayed in a single 2D gel represent only a portion of all the proteins that are present in a sample. Thus, in our study, in addition to 2-DE, we further applied HPLC-Chip/Q-TOF technology to perform proteomics screening. The combined use of HPLC-Chip/Q-TOF and 2D-PAGE methodologies afforded a number of advantages over the use of a single proteomic methodology, including the ability to confirm experimental results and accuracy by essentially comparing results from each method. Because each method has its own unique set of advantages, the combined use of both tech-
niques enhanced our confidence in the reported findings. It is important to point out that, though distinct sets of glycolysis and gluconeogenesis proteins were identified with each proteomic platform (HPLC-Chip/Q-TOF and 2D-PAGE), the results observed seemed to point in the same direction. All of the dysregulated proteins identified by proteomics analyses were further validated by qRT-PCR and/or Western blotting assays. For instance, G6pc and Pepck, two enzymes involved in gluconeogenesis, were found to be decreasingly expressed in FADD-D MEFs and livers by proteomics analyses. Later qRT-PCR and Western blots confirmed these results. However, the mRNA levels of a few proteins did not always agree with proteomics results, suggesting that the observed alterations in levels of these proteins were caused by post-transcriptional changes in the stability of mRNA and/or protein. For example, consistent with observations from proteomics, the expression of GS markedly increased at protein levels in FADD-D livers by Western blotting analysis, but the mRNA level was found to be reduced. As we know, although abundant mRNAs usually result in high protein levels (50), the general correlation between mRNA levels and protein abundance is often poor (51), which might be because of the regulatory complexity of mRNA translation and protein stability. Additionally, although the directional changes for all proteins analyzed by Western blotting were consistent with the proteomics data, the intensity differences seen by the

Fig. 5. Enhanced Akt phosphorylation in the liver of FADD-D mice. A, Western blots of liver tissue lysates from FADD-D and control mice were performed after insulin treatment to assess phospho-Akt, phospho-GSK3β, as well as total Akt, GSK3β, GS and GAPDH expression levels (n = 3 for each group). B and C, Densitometric analysis of phospho-Akt (B) and phospho-GSK3β levels (C) in (A). D and E, Amplification of Akt phosphorylation (D) and GSK3β phosphorylation (E) after insulin stimulation. F, GS immunostaining in liver sections of FADD-D and control mice (n = 3 for each group). Scale bar, 20 μm. G, Immunohistochemistry with anti-Foxo1 antibody (green) and Hoechst (blue) to show the localization of Foxo1 in liver sections of FADD-D and control mice (n = 4 for each group). Scale bar, 20 μm. Data are presented as means ± S.E. Statistical significance was assessed by two-tailed Student’s t test, *p < 0.05.
immunoblotting analysis did not always agree with the proteomics results. For example, the intensity of pyruvate kinase isozymes R/L (Kpyr) in FADD-D liver was 3.4-fold compared with control liver by proteomics analysis, whereas on the immunoblotting analysis, the intensity of Kpyr in FADD-D liver was only about 1.3-fold of that in control liver. Actually, there might be many technical reasons for differences in the absolute values (e.g., different methods of detection and variations in how software packages define the outlines of bands/spots) as well as biological reasons (protein isoforms differing in charge that are separated by 2-DE but co-migrate in the 1D gels used for immunoblotting). Proteomics analysis is known to suffer from a high rate of false-negative results, thus emphasizing the importance of performing replicate proteomic experiments, and validating the data by orthogonal approaches. In general, qRT-PCR and immunoblotting confirmed most of the quantitative results detected by proteomics screening.

As an important part of metabolism, glucose homeostasis is maintained by the balance of glucose storage as glycogen, glucose utilization by glycolysis and glucose production through gluconeogenesis and glycogenolysis (20). Our analysis of cellular and mice liver comparative proteomics revealed a special role for FADD in glucose metabolism. Glycogen synthase (GS) and glycogen phosphorylase (GP), responsible for glycogen synthesis and breakdown respectively, coordinate to regulate glycogen metabolism (52, 53). The increased expression of protein serine/threonine protein phosphatase PP1-alpha catalytic subunit (Ppp1ca), as indicated in our proteomics and Western blot assays, will inactivate GP and inhibit glycogen breakdown (52). On the other hand, GS is inactivated by multisite phosphorylation involving several protein kinase, such as GSK3β, which is regulated by Akt (28, 29, 54, 55). In FADD-D mice, the highly phosphorylated Akt increased the active form of GS through elevated GSK3β phosphorylation, leading to enhanced glycogen synthesis as we have detected. Another protein with increased expression identified in the proteomics of MEFs and liver in FADD-D mice was Gck, which catalyzes glucose into glucose-6-phosphate (20), initiating glycogen synthesis. Gck also plays a critical role in glycolysis, together with the changed expression of other enzymes involved in glycolysis (20, 56), such as phosphoglycerate mutase 1 (Pgaml) and L-lactate dehydrogenase A chain (Ldha), enhancing the use of glucose in FADD-D mice. On the contrary, as a result of Akt phosphorylation-induced inactivation of Foxo1, the protein and mRNA expressions of G6pc and Pepck, two key enzymes in gluconeogenesis and glycogenolysis controlled by Foxo1, were suppressed in FADD-D mice liver, leading to decreased glucose production (30). Collectively, the changes in the protein and mRNA levels of these enzymes involved in glucose metabolism contributed to the decreased glucose production,
Role of FADD Phosphorylation in Glucose Homeostasis

In subsequent studies, we will put emphasis on identifying the possible mediators that might serve as the link between FADD-D and enhanced Akt activation.

In conclusion, by comparative proteomics discovery and physiological validation, our study provides evidence for the first time, that FADD, especially its phosphorylation form, has an impact on glucose homeostasis, another nonapoptotic function compared with previous reports. We suggest that FADD-D might affect the expression of enzymes in glucose metabolism, decreasing the blood glucose level. This effect might have a correlation with increased Akt phosphorylation in FADD-D, providing a potential drug target in the treatment of diabetes. Further studies may focus on clarifying the relationships between FADD and Akt, and investigating mechanisms underlying the effect of FADD on glucose metabolism in detail.

Acknowledgements—We thank Dr. Luan Shu, Jiangsu Provincial Academy of Chinese Medicine, for critical reading and comments.

* This work was supported by grants from the Chinese National Nature Sciences Foundation (81121062, 31071196, 31200572, 30425009, 30330530, 30270291), the Ministry of Science and Technology of China (2012AAA020304, 2008BAI51B01), the Jiangsu Provincial Nature Science Foundation (BK2011228, BZ2011048, BZ2010074, BZ2012050, BK2011573), Bureau of Science and Technology of Changzhou (CZ20100008, CE20115034, C220110028, C220115006, CM20122003, C220120004).

§ These authors contribute equally.

1. Boldin, M. P., Varfolomeev, E. E., Pancer, Z., Mett, I. L., Camonis, J. H., and Wallach, D. (1995) A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J. Biol. Chem. 270, 7795–7798
2. Chinnaiyan, A. M., Oroucke, K., Tewari, M., and Dixit, V. M. (1995) FADD, A Novel Death Domain-Containing Protein, Interacts With the Death Domain of Fas and Initiates Apoptosis. Cell. 81, 505–512
3. Zhang, J., and Winoto, A. (1996) A mouse Fas-associated protein with homology to the human Mort1/FADD protein is essential for Fas-induced apoptosis. Mol. Cell. Biol. 16, 2756–2763
4. Kim, P. K., Dutra, A. S., Chandrasekharappa, S. C., and Puck, J. M. (1996) Genomic structure and mapping of human FADD, an intracellular mediator of lymphocyte apoptosis. J. Immunol. 157, 5461–5466
5. Schneider, P., Thome, M., Burns, K., Bodmer, J. L., Hoffmann, K., Kataoka, T., Holler, N., and Tschopp, J. (1997) TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunology 7, 831–836
6. Kuang, A. A., Diehl, G. E., Zhang, J., and Winoto, A. (2000) FADD is required for DR4- and DR5-mediated apoptosis: loss of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts. J. Biol. Chem. 275, 25065–25068
7. Zhang, J., Cado, D., Chen, A., Kabra, N. H., and Winoto, A. (1998) Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature 392, 296–300
8. Hua, Z. C., Sohn, S. J., Kang, C., Cado, D., and Winoto, A. (2003) A function of Fas-associated death domain protein in cell cycle progression localized to a single amino acid at its C-terminal region. Immunity 18, 513–521

Fig. 7. Schematic representation of the altered glucose homeostasis in FADD-D mice. Elevated Akt phosphorylation in FADD-D mice inactivated GSK3β and increased active form of GS, together with the highly expressed Gck and Ppp1ca, leading to enhanced glycogen accumulation. On the other hand, Akt phosphorylated and inactivated Foxo1, which regulates the transcription of G6pc and Pepck, suppressing gluconeogenesis and glycogenolysis. The expression levels of proteins involved in glycolysis were also changed. As a result, there was a low blood glucose level in FADD-D mice. The purple ellipses indicate proteins with changed expression we have found in proteomics and verified by Western blots.
Role of FADD Phosphorylation in Glucose Homeostasis

53. Suzuki, Y., Lanner, C., Kim, J. H., Vilaro, P. G., Zhang, H., Yang, J., Cooper, L. D., Steele, M., Kennedy, A., Bock, C. B., Scrimgeour, A., Lawrence, J. C., Jr., and DePaoli-Roach, A. A. (2001) Insulin control of glycogen metabolism in knockout mice lacking the muscle-specific protein phosphatase PP1G/RGL. Mol. Cell. Biol. 21, 2683–2694

54. Pugazhenthi, S., and Khandelwal, R. L. (1995) Regulation of glycogen synthase activation in isolated hepatocytes. Mol. Cell. Biochem. 149–150, 95–101

55. Roach, R. J., and Larner, J. (1977) Covalent phosphorylation in the regulation glycogen synthase activity. Mol. Cell. Biochem. 15, 179–200

56. Kurland, I. J., and Pilkis, S. J. (1989) Indirect versus direct routes of hepatic glycogen synthesis. FASEB J. 3, 2277–2281

57. Cheng, W., Wang, L., Zhang, R., Du, P., Yang, B., Zhuang, H., Tang, B., Yao, C., Yu, M., Wang, Y., Zhang, J., Yin, W., Li, J., Zheng, W., Lu, M., and Hua, Z. (2012) Regulation of protein kinase C inactivation by Fas-associated protein with death domain. J. Biol. Chem. 287, 26126–26135

58. Manning, B. D., and Cantley, L. C. (2007) AKT/PKB signaling: navigating downstream. Cell 129, 1261–1274

59. Alessi, D. R., and Cohen, P. (1998) Mechanism of activation and function of protein kinase B. Curr. Opin. Genet. Dev. 8, 55–62

60. Meier, R., Thelen, M., and Hemmings, B. A. (1998) Inactivation and dephosphorylation of protein kinase Balpha (PKBalpha) promoted by hyperosmotic stress. EMBO J. 17, 7294–7303

61. Brazil, D. P., Yang, Z. Z., and Hemmings, B. A. (2004) Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem. Sci. 29, 233–242

62. Du, K., Herzog, S., Kulkarni, R. N., and Montminy, M. (2003) TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science 300, 1574–1577

63. Zinker, B. A., Rondinone, C. M., Trevillyan, J. M., Gum, R. J., Clampit, J. E., Waring, J. F., Xie, N., Wilcox, D., Jacobson, P., Frost, L., Kroeger, P. E., Reilly, R. M., Koterski, S., Opgenorth, T. J., Ulirich, R. G., Crosby, S., Butler, M., Murray, S. F., McKay, R. A., Bhanot, S., Monia, B. P., and Jirousek, M. R. (2002) PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc. Natl. Acad. Sci. U.S.A. 99, 11357–11362